Teva Pharmaceutical Industries is selling the remaining assets of its specialty global women’s health business for $1.38 billion.
It will use the proceeds from the sales – combined with those of the recent Paragard sale – to progress repayment of term loan debt.
The remaining assets have been sold off in two separate agreements.
The first is to CVC Capital Partners Fund VI who will acquire a portfolio of products across contraception, fertility, menopause and osteoporosis for $703 million.
The second agreement involves Foundation Consumer Healthcare acquiring Plan B One-Step and Teva’s value brands of emergency contraception, Take Action, Aftera, and Next Choice One Dose for $675 million.
Teva is also planning the divestiture of the Oncology and Pain business in Europe.